600196 复星医药
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)4.3255.2878.90612.41310.635
总资产报酬率 ROA (%)1.7582.1633.7225.3434.584
投入资产回报率 ROIC (%)2.2302.7584.8446.9465.803

边际利润分析
销售毛利率 (%)48.59747.83747.28448.14454.685
营业利润率 (%)10.0537.98910.59516.15615.578
息税前利润/营业总收入 (%)12.70110.26311.88116.67917.825
净利润/营业总收入 (%)8.1476.9938.98112.75613.000

收益指标分析
经营活动净收益/利润总额(%)50.4333.53756.95431.74036.604
价值变动净收益/利润总额(%)45.33694.18141.08782.35061.196
营业外收支净额/利润总额(%)-1.173-1.315-1.799-4.301-0.926

偿债能力分析
流动比率 (X)0.9201.0011.0591.0381.009
速动比率 (X)0.7220.7780.8530.8510.801
资产负债率 (%)48.64550.10449.50848.15045.051
带息债务/全部投入资本 (%)37.21338.27337.44735.13736.989
股东权益/带息债务 (%)140.054133.295142.559158.135152.417
股东权益/负债合计 (%)84.36180.35584.03187.24398.127
利息保障倍数 (X)4.5944.3178.06614.0227.459

营运能力分析
应收账款周转天数 (天)70.13666.22655.77148.88353.051
存货周转天数 (天)127.212120.19495.98394.631119.314